Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum ABFRA:6Y1 +0.44%53 3-Year RORE % is 68.49 as of Apr. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 53/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 776 Medical Devices & Instruments companies, Integrum AB ranks better than 89.05% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Integrum AB's 3-Year RORE % for the quarter that ended in Apr. 2026 was 68.49%.
The industry rank for Integrum AB's 3-Year RORE % or its related term are showing as below:
FRA:6Y1's 3-Year RORE % is ranked better than 89.05% of 776
companies
in the Medical Devices & Instruments industry
Industry Median: -4.23
vs FRA:6Y1: 68.49
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Integrum AB 3-Year RORE % Related Terms
Integrum AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Integrum AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Y1 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Integrum AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Integrum AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 3-year before.
Integrum AB (FRA:6Y1) has a 3-Year RORE % of 68.49 as of Apr. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integrum AB and its competitors. According to the industry distribution chart, Integrum AB ranks #85 out of 776 companies in the Medical Devices & Instruments industry, placing it in the top 11%.
Is Integrum AB's 3-Year RORE % too high?
Integrum AB's current 3-Year RORE % is 68.49. Based on the distribution chart, Integrum AB ranks #85 out of 776 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Integrum AB has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #85 out of 776 companies for 3-Year RORE %. This places Integrum AB in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integrum AB and its competitors. Integrum AB's current 3-Year RORE % is 68.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.69 — trading 55.1% below its estimated fair value. The current 3-Year RORE % is 68.49. Integrum AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current 3-Year RORE % is 68.49 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (FRA:6Y1) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of €0.69 is trading 55.1% below its estimated GF Value™ of €1.54.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for FRA:6Y1:
3-Year RORE %: 68.49
GF Value™: €1.54 vs. price of €0.69 (55.1% below fair value)
No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
53GF Score
Get the complete analysis for FRA:6Y1
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Y1 has been successfully added to your 
